Genome Editing Market
授權報價
| Single User | $4,799 USD |
| Multi User | $7,999 USD |
| Enterprise / Global Site Licence | $17,999 USD |
完整報告名稱與涵蓋範圍
Genome Editing Market by Type of Payment Method Employed, Type of Gene Editing Technique, Gene Editing Approach, Type of Gene Delivery Method, Gene Delivery Modality, Type of Therapy, Application Area, Type of End-User, Geographical Regions, and Leading Industry Players – Trends and Forecast Till 2035
報告摘要
GENOME EDITING MARKET: OVERVIEW
As per Roots Analysis, the global genome editing market is estimated to grow from USD 5.29 billion in the current year to USD 13.36 billion by 2035, at an impressive CAGR of 10.8%, during the forecast period, till 2035.
Genome Editing Market: Growth and Trends
Genome editing refers to a set of genetic engineering techniques that allow researchers to insert, delete, or replace segments of DNA within the genome of an organism. Three broad classes of tools have emerged in gene editing over the past three decades namely, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the CRISPR-Cas system. Presently, CRISPR genome editing tool is widely used for gene editing owing to its precision, cost efficiency, and ease of design.
The clinical rationale for genome editing has strengthened significantly, driven by the substantial global burden of genetic disorders and the significant contribution of inherited genetic conditions to infant mortality. This disease burden, combined with maturing regulatory pathways for cell and gene therapies, has pushed genome editing from a research tool into a commercially viable therapeutic modality. Presently, over a thousand active clinical programs are currently evaluating gene-edited and gene-based interventions.
Pharmaceutical and biotechnology companies are increasingly licensing external editing platforms rather than building proprietary toolkits due to the high expense of in-house discovery and the regulatory complexity of gene-edited product development. This has created a distinct technology-licensing economy that sits at the center of the genome editing value chain and is a key structural feature distributors and channel partners should understand before entering this space.
Growth Drivers: Factors Fueling Expansion of the Global Genome Editing Market
Market growth is being driven by the steady clinical validation of CRISPR-based cell and gene therapies. Further, the expanding disease scope of genome editing beyond monogenic disorders into oncology, neurology and metabolic disease, and rising out-licensing activity among technology originators are the key drivers of the market. The transition toward next-generation base and prime editing tools, which offer more precise edits with fewer off-target effects, is widening the addressable therapeutic scope of the field. Growing agricultural and diagnostic applications of genome editing are reinforcing this trajectory outside of core therapeutics.
Market Challenges: Critical Barriers Hindering Progress
Despite strong momentum, the industry players are witnessing several challenges that impede market growth. In vivo genome editing remains limited by immunogenicity, off-target effects, and inadequate tissue specificity. On the other hand, ex vivo approaches are hindered by high costs and operational complexity. Additionally, fragmented CRISPR intellectual property and evolving regulatory frameworks continue to create licensing challenges and uncertainty around product approvals.
Genome Editing Market Segments
The market sizing and opportunity analysis has been segmented across the following parameters:
By Type of Payment Method Employed
• Upfront Payments
• Milestone Payments
By Type of Gene Editing Technique
• CRISPR-Cas System
• TALENs
• Meganucleases
• ZFNs
• Other Techniques
By Gene Editing Approach
• Gene Knock-Out
• Gene Knock-In
By Type of Gene Delivery Method
• Ex Vivo
• In Vivo
By Gene Delivery Modality
• Viral Vectors
• Non-Viral Vectors
By Type of Therapy
• Cell Therapies
• Gene Therapies
• Other Therapies
By Application Area
• Drug Discovery and Development
• Diagnostics
By Type of End-User
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
By Geographical Regions
• North America
• US
• Canada
• Europe
• Germany
• France
• Ireland
• Asia-Pacific
• China
• Japan
• South Korea
Genome Editing Market: Key Segmentation Insights
By Payment Method
Upfront payments currently account for the largest share of the market. Capital commitment in the short term remains heavily weighted toward immediate technology acquisition and licensing rights to secure proprietary genome editing platforms. However, in the future, milestone-based payments segment is projected to hold the highest global market share by 2035 as licensing deals mature and more programs advance through clinical and commercial milestones.
By Gene Editing Technique
CRISPR-Cas systems dominate the technology landscape. This highest share is due to the versatility of the system and the emergence of refined variants such as base and prime editing that address earlier limitations around precision and off-target effects. Notably, this segment will continue to gain momentum, anticipated to register higher CAGR during the forecast period.
Market leadership is sustained by the platform’s inherent versatility and rapid structural refinements. Next-generation tools specifically base editing and prime editing are mitigating early safety and accuracy challenges like off-target cleavage and double-stranded DNA breaks, solidifying CRISPR's position as the primary clinical standard.
By Gene Editing Approach
Gene knock-out approaches hold the largest share of the global market. This highest share is due to their relative technical simplicity compared with knock-in strategies, which require more complex optimization to achieve precise sequence insertion.
By Gene Delivery Method
Ex vivo delivery leads by holding highest share of the market. This dominance is largely because modifying cells outside the body allows tighter quality control and lower off-target risk than in vivo delivery. In ex vivo genome editing, patient-derived cells are isolated, genetically modified under controlled laboratory conditions, rigorously tested for editing efficiency and safety, and then reinfused into the patient.
This approach enables precise quality control, minimizes off-target editing, and reduces systemic exposure to genome editing components, thereby improving the overall safety profile. Furthermore, ex vivo delivery is well suited for CRISPR-Cas, TALEN, and zinc finger nuclease-based therapies targeting hematopoietic stem cells and immune cells, which have demonstrated encouraging clinical outcomes.
By Gene Delivery Modality
Viral vectors currently account for the largest share of the genome editing market, owing to their high gene transfer efficiency, robust transgene expression, and extensive clinical validation. Delivery platforms such as adeno-associated viruses (AAVs), lentiviral vectors, and adenoviral vectors are widely used in both clinical trials and approved gene and cell therapies, particularly for ex vivo applications. Their established manufacturing processes, well-characterized safety profiles, and regulatory familiarity have further strengthened their market position.
However, non-viral delivery modalities are expected to witness the fastest CAGR during the forecast period. This shift is driven by increasing demand for safer, more scalable, and cost-effective delivery platforms. Technologies such as lipid nanoparticles (LNPs), polymer-based nanoparticles, electroporation, and other physical delivery methods eliminate the risk of insertional mutagenesis, reduce immunogenicity, and enable repeat dosing, making them particularly attractive for in vivo genome editing applications.
.
By Type of Therapy
Cell therapies represent the leading application by holding the highest share. This highest share reflects their broad utility across multiple disease areas. Genome-edited cell therapies, particularly CAR-T, TCR-T, and hematopoietic stem cell-based therapies, have demonstrated significant clinical success and benefit from the use of ex vivo editing, which enables precise genetic modification, stringent quality control, and improved safety. The expanding pipeline of autologous and allogeneic cell therapies, coupled with increasing regulatory approvals, manufacturing investments, and strategic collaborations, continues to strengthen the segment's market leadership.
On the other hand, gene therapy, which is more narrowly focused on rare and monogenic conditions, is expected to grow at a higher CAGR during the forecast period. This growth is driven by the rapid advancement of CRISPR-based, base editing, prime editing, and mRNA-enabled genome editing technologies, which are expanding therapeutic opportunities beyond rare monogenic disorders to include more prevalent genetic, metabolic, ophthalmic, cardiovascular, and neurological diseases.
By Application Area
Drug discovery and development dominate the market. This highest share is driven by the use of CRISPR-based screening to identify novel drug targets. Conversely, diagnostic applications, while smaller today, are expected to expand at a higher CAGR during the forecast period as genome editing tools are adapted for early disease detection.
By End User
Pharmaceutical and biotechnology companies capture the highest share of the market, consistent with the fact that roughly 90% of technology licensing and integration agreements in this space are inked with commercial rather than academic entities.
North America Holds the Highest Share and Asia-Pacific Grows at Higher CAGR
According to our projections, North America leads the global market and is likely to remain dominant in the future. This growth is underpinned by the concentration of technology developers, the highest volume of licensing transactions and the largest pool of venture and institutional capital directed toward the sector.
Example Players in Genome Editing Market
• Arcturus Therapeutics
• ArsenalBio
• Avectas
• Beam Therapeutics
• Bio-Sourcing
• Caribou Biosciences
• Century Therapeutics
• CRISPR Therapeutics
• Editas Medicine
• Flash BioSolutions
• Graphite Bio
• Intellia Therapeutics
• NTrans Technologies
• OXGENE
• Prime Medicine
• Revvity
• Vor Biopharma
Expert Interview and Industry Insights
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:
• Chief Executive Officer, Large Organization, US
• Chief Scientific Officer, Mid-Sized Organization, US
• Chief Technology Officer, Large Organization, Europe
• Vice President, Business Development, Large Organization, US
• Head of Research, Academic Institute, Asia-Pacific
• Chief Medical Officer, Mid-Sized Organization, US
GENOME EDITING MARKET: RESEARCH COVERAGE
• Market Sizing and Opportunity Analysis: An in-depth analysis of the genome editing market size and forecast across key segments, including type of payment method employed, type of gene editing technique, gene editing approach, type of gene delivery method, gene delivery modality, type of therapy, application area, type of end-user and geography.
• Technology and Developer Landscape: A detailed assessment of the current technology landscape for genome editing, evaluated by type of gene editing technique, gene editing approach, gene delivery method, gene delivery modality, highest phase of development supported, therapeutic area and application area, along with an analysis of technology providers by year of establishment, company size, location of headquarters and operating model.
• Company Competitiveness Analysis: An insightful competitiveness analysis of genome editing technology providers, benchmarked on company strength and technology strength, segmented across peer groups headquartered in North America, Europe, and Asia-Pacific.
• Company Profiles: Elaborate and short profiles of prominent players developing genome editing technologies across North America, Europe and Asia-Pacific, featuring company overview, technology portfolio, recent developments, and an informed future outlook.
• Partnerships and Collaborations Analysis: A comprehensive assessment of partnership activity among genome editing technology providers since 2018, evaluated by year, type of partnership, focus area, geography, and most active players.
• Patent Analysis: An in-depth analysis of patents filed and granted to genome editing technology providers since 2018, evaluated by publication year, geography, CPC classification, and applicant type, along with patent benchmarking, valuation, and citation analysis.
• Funding and Investment Analysis: A comprehensive assessment of funding and investment activity among genome editing technology providers since 2018, evaluated by year, type of funding, amount invested, geography, and most active players and investors.
• Market Impact Analysis: An in-depth analysis of the drivers, restraints, opportunities, and challenges influencing the growth of the genome editing market.
Key Questions Answered in this Report
• How large is the genome editing market today, and how large will it be by 2035?
• Which gene editing techniques, delivery methods and delivery modalities are gaining or losing share?
• Which companies are best positioned across each segment, and how deep is their technology and pipeline portfolio?
• How is the balance between upfront and milestone-based licensing likely to evolve?
• Which application areas beyond drug discovery offer the strongest medium-term upside?
• Which geographies offer the best combination of near-term revenue and long-term growth rate?
Reasons to Buy this Report
Distributors evaluating the genome editing opportunity need more than a headline market size figure. This report is built to support commercial decision-making, not just awareness, and differentiates itself on the following counts:
• Top-Down and Bottom-Up Triangulated Forecasting: Revenue projections for each segment are cross-validated using both technology-adoption trends and company-level deal data, reducing forecast risk for investors and channel partners.
• Primary Research: Insights are grounded in interviews with CEOs, chief scientific officers, and business development leaders across large, mid-sized and academic organizations, not desk research alone.
• Investor-Grade Financial Context: Company profiles include funding history, recent capital deployment and partnership activity, positioned for use in diligence and business case development.
• Patent and IP Landscape Clarity: A dedicated patent benchmarking chapter helps distributors and licensees navigate the fragmented CRISPR intellectual property landscape before entering supply or distribution agreements.
Additional Benefits
• Complementary Insights Pack
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older
目錄 Table of Contents
1. BACKGROUND
1.1. Context
1.2. Project Objectives
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Introduction to Gene Editing
6.2.1. Evolution of Gene Editing
6.2.2. Gene Editing Technologies
6.2.2.1. CRISPR - CAS System
6.2.2.2. Transcription Activator-Like Effector Nucleases (TALENs)
6.2.2.3. Zinc Finger Nucleases (ZFNs)
6.2.2.4. Meganucleases / Homing Endonucleases
6.3. Applications of Genome Editing Technologies
6.4. Other Emerging Technologies
6.5. Concluding Remarks
7. MARKET LANDSCAPE: GENOME EDITING TECHNOLOGIES
7.1. Chapter Overview
7.2. Genome Editing: Technology Landscape
7.2.1. Analysis by Type of Gene Editing Technique
7.2.2. Analysis by Type of Gene Editing Approach
7.2.3. Analysis by Type of Gene Delivery Method
7.2.4. Analysis by Type of Gene Delivery Modality
7.2.5. Analysis by Highest Phase of Drug Development Supported
7.2.6. Analysis by Therapeutic Area
7.2.7. Analysis by Application Area
7.3. Genome Editing: Technology Providers Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Analysis by Company Size and Location of Headquarters
7.3.5. Most Active Players: Analysis by Number of Technologies
7.3.6. Analysis by Operational Model
8. TECHNOLOGY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions / Key Parameters
8.3. Methodology
8.4. Technology Competitiveness Analysis
8.4.1. Genome Editing Technologies Offered by Players Headquartered in North America
8.4.2. Genome Editing Technologies Offered by Players Headquartered in Europe
8.4.3. Genome Editing Technologies Offered by Players Headquartered in Asia-Pacific, Middle East and North Africa, and Latin America
9. GENOME EDITING MARKET: COMPANY PROFILES OF PLAYERS BASED IN NORTH AMERICA
9.1. Chapter Overview
9.2. Arcturus Therapeutics
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Technology Portfolio
9.2.4. Recent Developments and Future Outlook
9.3. Arsenal Bio
9.3.1. Company Overview
9.3.2. Technology Portfolio
9.3.3. Recent Developments and Future Outlook
9.4. Beam Therapeutics
9.4.1. Company Overview
9.4.2. Financial Information
9.4.3. Technology Portfolio
9.4.4. Recent Developments and Future Outlook
9.5. Caribou Biosciences
9.5.1. Company Overview
9.5.2. Financial Information
9.5.3. Technology Portfolio
9.5.4. Recent Developments and Future Outlook
9.6. Century Therapeutics
9.6.1. Company Overview
9.6.2. Financial Information
9.6.3. Technology Portfolio
9.6.4. Recent Developments and Future Outlook
9.7. CRISPR Therapeutics
9.7.1. Company Overview
9.7.2. Financial Information
9.7.3. Technology Portfolio
9.7.4. Recent Developments and Future Outlook
9.8. Editas Medicine
9.8.1. Company Overview
9.8.2. Financial Information
9.8.3. Technology Portfolio
9.8.4. Recent Developments and Future Outlook
9.9. Intellia Therapeutics
9.9.1. Company Overview
9.9.2. Financial Information
9.9.3. Technology Portfolio
9.9.4. Recent Developments and Future Outlook
9.10. Prime Medicine
9.10.1. Company Overview
9.10.2. Technology Portfolio
9.10.3. Recent Developments and Future Outlook
9.11. Vor Biopharma
9.11.1. Company Overview
9.11.2. Technology Portfolio
9.11.3. Recent Developments and Future Outlook
10. GENOME EDITING MARKET: COMPANY PROFILES OF PLAYERS BASED IN EUROPE
10.1. Chapter Overview
10.2. Avectas
10.2.1. Company Overview
10.2.2. Technology Portfolio
10.3. Bio-Sourcing
10.3.1. Company Overview
10.3.2. Technology Portfolio
10.4. Flash Therapeutics
10.4.1. Company Overview
10.4.2. Technology Portfolio
10.5. NTrans Technologies
10.5.1. Company Overview
10.5.2. Technology Portfolio
10.6. OXGENE (Acquired by WuXi AppTec)
10.6.1. Company Overview
10.6.2. Technology Portfolio
10.7. Revvity (formerly known as Horizon Discovery)
10.7.1. Company Overview
10.7.2. Technology Portfolio
11. GENOME EDITING MARKET: COMPANY PROFILES OF PLAYERS BASED IN ASIA-PACIFIC AND REST OF THE WORLD
11.1. Chapter Overview
11.2. Edigene
11.2.1. Company Overview
11.2.2. Technology Portfolio
11.3. Fortgen
11.3.1. Company Overview
11.3.2. Technology Portfolio
11.4. G+FLAS Life Sciences
11.4.1. Company Overview
11.4.2. Technology Portfolio
11.5. TargetGene Biotechnologies
11.5.1. Company Overview
11.5.2. Technology Portfolio
12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Genome Editing Technologies: Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year and Type of Partnership
12.3.4. Analysis by Purpose of Partnership
12.3.5. Analysis by Type of Partner
12.3.6. Analysis by Location of Headquarters of Partner
12.3.7. Most Active Players: Analysis by Number of Partnerships
12.3.8. Analysis by Geography
12.3.8.1. Local and International Agreements
12.3.8.2. Intercontinental and Intracontinental Agreements
13. PATENT ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Genome Editing Domain: Patent Analysis
13.3.1. Analysis by Publication Year
13.3.2. Analysis by Type of Patent and Publication Year
13.3.3. Analysis by Geography
13.3.4. Analysis by CPC Symbols
13.3.5. Leading Industry Players: Analysis by Number of Patents
13.4. Genome Editing Domain: Patent Benchmarking Analysis
13.4.1. Analysis by Patent Characteristics
13.4.2. Analysis by Leading Industry Players
13.5. Patent Valuation Analysis
14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Funding Models
14.3. Genome Editing Market: Funding and Investment Analysis
14.3.1. Analysis by Year of Funding
14.3.1.1. Cumulative Year-wise Trend of Funding Instances
14.3.1.2. Cumulative Year-wise Trend of Amount Invested
14.3.2. Analysis by Type of Funding
14.3.2.1. Analysis by Funding Instances
14.3.2.2. Analysis by Amount Invested
14.3.3. Analysis by Year and Type of Funding
14.3.4. Analysis by Geography
14.3.5. Most Active Players: Analysis by Amount Invested and Number of Funding Instances
14.3.6. Leading Investors: Analysis by Number of Funding Instances
14.4. Concluding Remarks
15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
15.1. Chapter Overview
15.2. Market Drivers
15.3. Market Restraints
15.4. Market Opportunities
15.5. Market Challenges
15.6. Conclusion
16. GENOME EDITING TECHNOLOGIES MARKET
16.1. Chapter Overview
16.2. Assumptions and Methodology
16.3. Genome Editing Technologies Market: Forecasted Estimates, till 2035
16.3.1. Scenario Analysis
16.3.1.1. Conservative Scenario
16.3.1.2. Optimistic Scenario
16.4. Key Market Segmentations
17. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF PAYMENT METHOD EMPLOYED
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Genome Editing Technologies Market: Distribution by Type of Payment Method Employed
17.3.1. Genome Editing Technologies Market for Milestone Payments: Forecasted Estimates, till 2035
17.3.2. Genome Editing Technologies Market for Upfront Payments: Forecasted Estimates, till 2035
17.4. Data Triangulation
18. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF GENE EDITING TECHNIQUE
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Genome Editing Technologies Market: Distribution by Type of Gene Editing Technique
18.3.1. Genome Editing Technologies Market for CRISPR-Cas System: Forecasted Estimates, till 2035
18.3.2. Genome Editing Technologies Market for TALENs: Forecasted Estimates, till 2035
18.3.3. Genome Editing Technologies Market for Meganucleases: Forecasted Estimates, till 2035
18.3.4. Genome Editing Technologies Market for ZFNs: Forecasted Estimates, till 2035
18.3.5. Genome Editing Technologies Market for Other Techniques: Forecasted Estimates, till 2035
18.4. Data Triangulation
19. GENOME EDITING TECHNOLOGIES MARKET, BY GENE EDITING APPROACH
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Genome Editing Technologies Market: Distribution by Gene Editing Approach
19.3.1. Genome Editing Technologies Market for Gene Knock-Out Approaches: Forecasted Estimates, till 2035
19.3.2. Genome Editing Technologies Market for Gene Knock-In Approaches: Forecasted Estimates, till 2035
19.4. Data Triangulation
20. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY METHOD
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Genome Editing Technologies Market: Distribution by Gene Delivery Method
20.3.1. Genome Editing Technologies Market for Ex Vivo Delivery Methods: Forecasted Estimates, till 2035
20.3.2. Genome Editing Technologies Market for In Vivo Delivery Methods: Forecasted Estimates, till 2035
20.4. Data Triangulation
21. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY MODALITY
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Genome Editing Technologies Market: Distribution by Gene Delivery Modality
21.3.1. Genome Editing Technologies Market for Viral Vectors: Forecasted Estimates, till 2035
21.3.2. Genome Editing Technologies Market for Non-Viral Vectors: Forecasted Estimates, till 2035
21.4. Data Triangulation
22. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF THERAPY
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Genome Editing Technologies Market: Distribution by Type of Therapy
22.3.1. Genome Editing Technologies Market for Cell Therapies: Forecasted Estimates, till 2035
22.3.2. Genome Editing Technologies Market for Gene Therapies: Forecasted Estimates, till 2035
22.3.3. Genome Editing Technologies Market for Other Therapies: Forecasted Estimates, till 2035
22.4. Data Triangulation
23. GENOME EDITING TECHNOLOGIES MARKET, BY APPLICATION AREA
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Genome Editing Technologies Market: Distribution by Application Area
23.3.1. Genome Editing Technologies Market for Drug Discovery and Development: Forecasted Estimates, till 2035
23.3.2. Genome Editing Technologies Market for Diagnostics: Forecasted Estimates, till 2035
23.4. Data Triangulation
24. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF END USER
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Genome Editing Technologies Market: Distribution by Type of End User
24.3.1. Genome Editing Technologies Market for Pharmaceutical and Biotechnology Companies: Forecasted Estimates, till 2035
24.3.2. Genome Editing Technologies Market for Academic and Research Institutes: Forecasted Estimates, till 2035
24.4. Data Triangulation
25. GENOME EDITING TECHNOLOGIES MARKET, BY KEY GEOGRAPHICAL REGIONS
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Genome Editing Technologies Market: Distribution by Key Geographical Regions
25.3.1. Genome Editing Technologies Market in North America: Forecasted Estimates, till 2035
25.3.1.1. Genome Editing Technologies Market in the US: Forecasted Estimates, till 2035
25.3.1.2. Genome Editing Technologies Market in Canada: Forecasted Estimates, till 2035
25.3.2. Genome Editing Technologies Market in Europe: Forecasted Estimates, till 2035
25.3.2.1. Genome Editing Technologies Market in Germany: Forecasted Estimates, till 2035
25.3.2.2. Genome Editing Technologies Market in France: Forecasted Estimates, till 2035
25.3.2.3. Genome Editing Technologies Market in Ireland: Forecasted Estimates, till 2035
25.3.3. Genome Editing Technologies Market in Asia-Pacific: Forecasted Estimates, till 2035
25.3.3.1. Genome Editing Technologies Market in South Korea: Forecasted Estimates, till 2035
25.3.3.2. Genome Editing Technologies Market in China: Forecasted Estimates, till 2035
25.3.3.3. Genome Editing Technologies Market in Japan: Forecasted Estimates, till 2035
25.4. Market Dynamics Assessment
25.4.1. Penetration Growth (P-G) Matrix
25.5. Data Triangulation
26. GENOME EDITING TECHNOLOGIES MARKET: LEADING INDUSTRY PLAYERS
26.1. Chapter Overview
26.2. Leading Industry Players
27. CONCLUDING INSIGHTS
28. EXECUTIVE INSIGHTS
29. APPENDIX 1: TABULATED DATA
30. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
圖表清單 List of Tables & Figures
Table 7.1 List of Genome Editing Technologies
Table 7.2 Genome Editing Technologies: Information on Type of Gene Editing Technique
Table 7.3 Genome Editing Technologies: Information on Type of Gene Editing Approach
Table 7.4 Genome Editing Technologies: Information on Type of Gene Delivery Method
Table 7.5 Genome Editing Technologies: Information on Type of Gene Delivery Modality
Table 7.6 Genome Editing Technologies: Information on Highest Phase of Drug Development Supported
Table 7.7 Genome Editing Technologies: Information on Therapeutic Area
Table 7.8 Genome Editing Technologies: Information on Application Area
Table 7.9 Genome Editing Technologies: List of Technology Providers
Table 7.10 Genome Editing Technology Providers: Information on Operational Model
Table 7.11 Genome Editing Technology Providers: Information on Product Centric Model and Technology Centric Model
Table 8.1 Genome Editing Technologies Provided by Players Headquartered in North America
Table 8.2 Genome Editing Technologies Provided by Players Headquartered in Europe
Table 8.3 Genome Editing Technologies Provided by Players Headquartered in Asia-Pacific, Middle East and North Africa, and Latin America
Table 9.1 Genome Editing Technology Providers: List of Companies Profiled
Table 9.2 Arcturus Therapeutics: Company Overview
Table 9.3 Arcturus Therapeutics: Technology Portfolio
Table 9.4 Arcturus Therapeutics: Recent Developments and Future Outlook
Table 9.5 Arsenal Bio: Company Overview
Table 9.6 Arsenal Bio: Technology Portfolio
Table 9.7 Arsenal Bio: Recent Developments and Future Outlook
Table 9.8 Beam Therapeutics: Company Overview
Table 9.9 Beam Therapeutics: Technology Portfolio
Table 9.10 Beam Therapeutics: Recent Developments and Future Outlook
Table 9.11 Caribou Biosciences: Company Overview
Table 9.12 Caribou Biosciences: Technology Portfolio
Table 9.13 Caribou Biosciences: Recent Developments and Future Outlook
Table 9.14 Century Therapeutics: Company Overview
Table 9.15 Century Therapeutics: Technology Portfolio
Table 9.16 Century Therapeutics: Recent Developments and Future Outlook
Table 9.17 CRISPR Therapeutics: Company Overview
Table 9.18 CRISPR Therapeutics: Technology Portfolio
Table 9.19 CRISPR Therapeutics: Recent Developments and Future Outlook
Table 9.20 Editas Medicine: Company Overview
Table 9.21 Editas Medicine: Technology Portfolio
Table 9.22 Editas Medicine: Recent Developments and Future Outlook
Table 9.23 Intellia Therapeutics: Company Overview
Table 9.24 Intellia Therapeutics: Technology Portfolio
Table 9.25 Intellia Therapeutics: Recent Developments and Future Outlook
Table 9.26 Prime Medicine: Company Overview
Table 9.27 Prime Medicine: Technology Portfolio
Table 9.28 Prime Medicine: Recent Developments and Future Outlook
Table 9.29 Vor Biopharma: Company Overview
Table 9.30 Vor Biopharma: Technology Portfolio
Table 9.31 Vor Biopharma: Recent Developments and Future Outlook
Table 10.1 Genome Editing Technology Providers: List of Companies Profiled
Table 10.2 Avectas: Company Overview
Table 10.3 Avectas: Technology Portfolio
Table 10.4 Bio-Sourcing: Company Overview
Table 10.5 Bio-Sourcing: Technology Portfolio
Table 10.6 Flash BioSolutions: Company Overview
Table 10.7 Flash BioSolutions: Technology Portfolio
Table 10.8 NTrans Technologies: Company Overview
Table 10.9 NTrans Technologies: Technology Portfolio
Table 10.10 OXGENE: Company Overview
Table 10.11 OXGENE: Technology Portfolio
Table 10.12 Revvity: Company Overview
Table 10.13 Revvity: Technology Portfolio
Table 11.1 Genome Editing Technology Providers: List of Companies Profiled
Table 11.2 Edigene: Company Overview
Table 11.3 Edigene: Technology Portfolio
Table 11.4 Fortgen: Company Overview
Table 11.5 Fortgen: Technology Portfolio
Table 11.6 G+FLAS Life Sciences: Company Overview
Table 11.7 G+FLAS Life Sciences: Technology Portfolio
Table 11.8 TargetGene Biotechnologies: Company Overview
Table 11.9 TargetGene Biotechnologies: Technology Portfolio
Table 12.1 Genome Editing Market: List of Partnerships and Collaborations
Table 12.2 Technology Licensing / Integration Agreements: Information on Purpose of Partnership
Table 12.3 Partnerships and Collaborations: Information on Type of Agreement
Table 13.1 Patent Analysis: Top CPC Sections
Table 13.2 Patent Analysis: Top CPC Symbols
Table 13.3 Patent Analysis: Top CPC Codes
Table 13.4 Patent Analysis: Summary of Benchmarking Analysis
Table 13.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 13.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 14.1 Genome Editing Market: List of Funding and Investments
Table 16.1 Genome Editing Technologies: Average Upfront Payment and Average Milestone Payment, 2018-2024 (USD Million)
Table 16.2 Licensing Deals: Tranches of Milestone Payments
Table 26.1 Leading Industry Players: Based on General Market Understanding
Table 26.2 Leading Industry Players: Based on Funding Amount Invested (USD Million)
Table 26.3 Leading Industry Players: Based on Number of Technology Licensing / Integration Deals
Table 28.1 Prorenata Biotech: Company Snapshot
Table 29.1 Genome Editing Technologies: Distribution by Type of Gene Editing Technique
Table 29.2 Genome Editing Technologies: Distribution by Type of Gene Editing Approach
Table 29.3 Genome Editing Technologies: Distribution by Type of Gene Delivery Method
Table 29.4 Genome Editing Technologies: Distribution by Type of Gene Delivery Modality
Table 29.5 Genome Editing Technologies: Distribution by Highest Phase of Drug Development Supported
Table 29.6 Genome Editing Technologies: Distribution by Therapeutic Area
Table 29.7 Genome Editing Technologies: Distribution by Application Area
Table 29.8 Genome Editing Technology Providers: Distribution by Year of Establishment
Table 29.9 Genome Editing Technology Providers: Distribution by Company Size
Table 29.10 Genome Editing Technology Providers: Distribution by Location of Headquarters
Table 29.11 Genome Editing Technology Providers: Distribution by Company Size and Location of Headquarters
Table 29.12 Most Active Players: Distribution by Number of Technologies
Table 29.13 Genome Editing Technology Providers: Distribution by Operational Model
Table 29.14 Genome Editing Technology Providers: Distribution by Product Centric Model
Table 29.15 Genome Editing Technology Providers: Distribution by Technology Centric Model
Table 29.16 Arcturus Therapeutics: Annual Revenues, Since FY 2021 (USD Million)
Table 29.17 Beam Therapeutics: Annual Revenues, Since FY 2021 (USD Million)
Table 29.18 Caribou Biosciences: Annual Revenues, Since FY 2021 (USD Million)
Table 29.19 Century Therapeutics: Annual Revenues, Since FY 2022 (USD Million)
Table 29.20 CRISPR Therapeutics: Annual Revenues, Since FY 2021 (USD Million)
Table 29.21 Editas Medicine: Annual Revenues, Since FY 2021 (USD Million)
Table 29.22 Intellia Therapeutics: Annual Revenues, Since FY 2021 (USD Million)
Table 29.23 Partnerships and Collaborations: Cumulative Year-wise Trend
Table 29.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 29.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 29.26 Technology Licensing Agreements / Technology Integration Agreements: Distribution by Purpose of Partnership
Table 29.27 Partnerships and Collaborations: Distribution by Type of Partner
Table 29.28 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Table 29.29 Most Active Players: Distribution by Number of Partnerships
Table 29.30 Partnership and Collaborations: Local and International Agreements
Table 29.31 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 29.32 Patent Analysis: Distribution by Type of Patent
Table 29.33 Patent Analysis: Distribution by Patent Application Year
Table 29.34 Patent Analysis: Distribution by Patent Publication Year
Table 29.35 Patent Analysis: Distribution by Type of Patents and Publication Year
Table 29.36 Patent Analysis: Distribution by Patent Jurisdiction
Table 29.37 Patent Analysis: Cumulative Year-wise Trend by Type of Applicant
Table 29.38 Leading Industry Players: Distribution by Number of Patents
Table 29.39 Leading Non-Industry Players: Distribution by Number of Patents
Table 29.40 Leading Individual Assignees: Distribution by Number of Patents
Table 29.41 Patent Analysis: Distribution by Patent Age
Table 29.42 Genome editing: Patent Valuation
Table 29.43 Funding and Investment Analysis: Cumulative Year-wise Trend
Table 29.44 Funding and Investment Analysis: Cumulative Year-wise Trend of Amount Invested (USD Million)
Table 29.45 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
Table 29.46 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 29.47 Funding and Investment Analysis: Distribution by Year and Type of Funding
Table 29.48 Funding and Investments: Distribution of Funding Instances by Geography
Table 29.49 Most Active Players: Distribution by Amount Invested and Number of Funding Instances
Table 29.50 Leading Investors: Distribution by Number of Funding Instances
Table 29.51 Global Genome Editing Technologies Market, Forecasted Estimates, till 2035 (USD Billion)
Table 29.52 Global Genome Editing Technologies Market, Forecasted Estimates, till 2035: Conservative Scenario (USD Billion)
Table 29.53 Global Genome Editing Technologies Market, Forecasted Estimates, till 2035: Optimistic Scenario (USD Billion)
Table 29.54 Genome Editing Technologies Market: Distribution by Type of Payment Method Employed
Table 29.55 Genome Editing Technologies Market for Milestone Payments: Forecasted Estimates, till 2035 (USD Million)
Table 29.56 Genome Editing Technologies Market for Upfront Payments: Forecasted Estimates, till 2035 (USD Million)
Table 29.57 Genome Editing Technologies Market: Distribution by Type of Gene Editing Technique
Table 29.58 Genome Editing Technologies Market for CRISPR-Cas System: Forecasted Estimates, till 2035 (USD Million)
Table 29.59 Genome Editing Technologies Market for TALENs: Forecasted Estimates, till 2035 (USD Million)
Table 29.60 Genome Editing Technologies Market for Meganucleases: Forecasted Estimates, till 2035 (USD Million)
Table 29.61 Genome Editing Technologies Market for ZFNs: Forecasted Estimates, till 2035 (USD Million)
Table 29.62 Genome Editing Technologies Market for Other Techniques: Forecasted Estimates, till 2035 (USD Million)
Table 29.63 Genome Editing Technologies Market: Distribution by Type of Gene Editing Approach
Table 29.64 Genome Editing Technologies Market for Gene Knock-Out: Forecasted Estimates, till 2035 (USD Million)
Table 29.65 Genome Editing Technologies Market for Gene Knock-In: Forecasted Estimates, till 2035 (USD Million)
Table 29.66 Genome Editing Technologies Market: Distribution by Type of Gene Delivery Method
Table 29.67 Genome Editing Technologies Market for Ex vivo: Forecasted Estimates, till 2035 (USD Million)
Table 29.68 Genome Editing Technologies Market for In vivo: Forecasted Estimates, till 2035 (USD Million)
Table 29.69 Genome Editing Technologies Market: Distribution by Type of Gene Delivery Modality
Table 29.70 Genome Editing Technologies Market for Viral Vectors: Forecasted Estimates, till 2035 (USD Million)
Table 29.71 Genome Editing Technologies Market for Non-Viral Vectors: Forecasted Estimates, till 2035 (USD Million)
Table 29.72 Genome Editing Technologies Market: Distribution by Type of Therapy
Table 29.73 Genome Editing Technologies Market for Cell Therapies: Forecasted Estimates, till 2035 (USD Million)
Table 29.74 Genome Editing Technologies Market for Gene Therapies: Forecasted Estimates, till 2035 (USD Million)
Table 29.75 Genome Editing Technologies Market for Other Therapies: Forecasted Estimates, till 2035 (USD Million)
Table 29.76 Genome Editing Technologies Market: Distribution by Application Area
Table 29.77 Genome Editing Technologies Market for Drug Discovery and Development: Forecasted Estimates, till 2035 (USD Million)
Table 29.78 Genome Editing Technologies Market for Diagnostics: Forecasted Estimates, till 2035 (USD Million)
Table 29.79 Genome Editing Technologies Market: Distribution by Type of End-User
Table 29.80 Genome Editing Technologies Market for Pharmaceutical and Biotechnology Companies: Forecasted Estimates, till 2035 (USD Million)
Table 29.81 Genome Editing Technologies Market for Academic and Research Institutes: Forecasted Estimates, till 2035 (USD Million)
Table 29.82 Genome Editing Technologies Market: Distribution by Geographical Regions
Table 29.83 Genome Editing Technologies Market in North America: Forecasted Estimates, till 2035 (USD Million)
Table 29.84 Genome Editing Technologies Market in the US: Forecasted Estimates, till 2035 (USD Million)
Table 29.85 Genome Editing Technologies Market in Canada: Forecasted Estimates, till 2035 (USD Million)
Table 29.86 Genome Editing Technologies Market in Europe: Forecasted Estimates till 2035 (USD Million)
Table 29.87 Genome Editing Technologies Market in Germany: Forecasted Estimates till 2035 (USD Million)
Table 29.88 Genome Editing Technologies Market in France: Forecasted Estimates till 2035 (USD Million)
Table 29.89 Genome Editing Technologies Market in Ireland: Forecasted Estimates till 2035 (USD Million)
Table 29.90 Genome Editing Technologies Market in Asia-Pacific: Forecasted Estimates, till 2035 (USD Million)
Table 29.91 Genome Editing Technologies Market in South Korea: Forecasted Estimates, till 2035 (USD Million)
Table 29.92 Genome Editing Technologies Market in China: Forecasted Estimates, till 2035 (USD Million)
Table 29.93 Genome Editing Technologies Market in Japan: Forecasted Estimates, till 2035 (USD Million)
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Key Market Segmentation
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Genome Editing Technology Landscape
Figure 5.2 Executive Summary: Recent Trends Analysis
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Genome Editing: Milestones Achieved in Gene Editing Domain
Figure 6.2 Types of Gene Editing Technologies
Figure 6.3 CRISPR / Cas System: Mechanism of Action
Figure 6.4 TALENs: Mechanism of Action
Figure 6.5 ZFNs: Mechanism of Action
Figure 6.6 Meganucleases / Homing Endonucleases: Mechanism of Action
Figure 6.7 Applications of Gene Editing Technologies
Figure 7.1 Genome Editing Technologies: Distribution by Type of Gene Editing Technique
Figure 7.2 Genome Editing Technologies: Distribution by Type of Gene Editing Approach
Figure 7.3 Genome Editing Technologies: Distribution by Type of Gene Delivery Method
Figure 7.4 Genome Editing Technologies: Distribution by Type of Gene Delivery Modality
Figure 7.5 Genome Editing Technologies: Distribution by Highest Phase of Drug Development Supported
Figure 7.6 Genome Editing Technologies: Distribution by Therapeutic Area
Figure 7.7 Genome Editing Technologies: Distribution by Application Area
Figure 7.8 Genome Editing Technology Providers: Distribution by Year of Establishment
Figure 7.9 Genome Editing Technology Providers: Distribution by Company Size
Figure 7.10 Genome Editing Technology Providers: Distribution by Location of Headquarters
Figure 7.11 Genome Editing Technology Providers: Distribution by Company Size and Location of Headquarters
Figure 7.12 Most Active Players: Distribution by Number of Technologies
Figure 7.13 Genome Editing Technology Providers: Distribution by Operational Model
Figure 7.14 Genome Editing Technology Providers: Distribution by Product Centric Model
Figure 7.15 Genome Editing Technology Providers: Distribution by Technology Centric Model
Figure 8.1 Genome Editing Technologies Developed by Players Headquartered in North America
Figure 8.2 Genome Editing Technologies Developed by Players Headquartered in Europe
Figure 8.3 Genome Editing Technologies Developed by Players Headquartered in Asia-Pacific, Middle East and North Africa, and Latin America
Figure 9.1 Arcturus Therapeutics: Annual Revenues, Since FY 2021 (USD Million)
Figure 9.2 Beam Therapeutics: Annual Revenues, Since FY 2021 (USD Million)
Figure 9.3 Caribou Biosciences: Annual Revenues, Since FY 2021 (USD Million)
Figure 9.4 Century Therapeutics: Annual Revenues, Since FY 2022 (USD Million)
Figure 9.5 CRISPR Therapeutics: Annual Revenues, Since FY 2021 (USD Million)
Figure 9.6 Editas Medicine: Annual Revenues, Since FY 2021 (USD Million)
Figure 9.7 Intellia Therapeutics: Annual Revenues, Since FY 2021 (USD Million)
Figure 12.1 Partnerships and Collaborations: Cumulative Year-wise Trend
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 12.4 Technology Licensing Agreements / Technology Integration Agreements: Distribution by Purpose of Partnership
Figure 12.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 12.6 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Figure 12.7 Most Active Players: Distribution by Number of Partnerships
Figure 12.8 Partnerships and Collaborations: Local and International Agreements
Figure 12.9 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 13.1 Patent Analysis: Distribution by Type of Patent
Figure 13.2 Patent Analysis: Distribution by Patent Application Year
Figure 13.3 Patent Analysis: Distribution by Patent Publication Year
Figure 13.4 Patent Analysis: Distribution by Type of Patent and Publication Year
Figure 13.5 Patent Analysis: Distribution by Patent Jurisdiction
Figure 13.6 Patent Analysis: Distribution by CPC Symbols
Figure 13.7 Patent Analysis: Cumulative Year-wise Trend by Type of Applicant
Figure 13.8 Leading Industry Players: Distribution by Number of Patents
Figure 13.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 13.10 Leading Individual Assignees: Distribution by Number of Patents
Figure 13.11 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 13.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 13.13 Patent Analysis: Distribution by Patent Age
Figure 13.14 Genome editing: Patent Valuation
Figure 14.1 Funding and Investment Analysis: Cumulative Year-wise Trend
Figure 14.2 Funding and Investment Analysis: Cumulative Year-wise Trend of Amount Invested (USD Million)
Figure 14.3 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
Figure 14.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 14.5 Funding and Investment Analysis: Distribution by Year and Type of Funding
Figure 14.6 Funding and Investments: Distribution of Funding Instances by Geography
Figure 14.7 Most Active Players: Distribution by Amount Invested and Number of Funding Instances
Figure 14.8 Leading Investors: Distribution by Number of Funding Instances
Figure 14.9 Funding and Investment Analysis: Summary of Investments
Figure 16.1 Licensing Agreements: Distribution of Financial Components
Figure 16.2 Licensing Agreements: Illustrative Scenario Based Opportunity Estimation
Figure 16.3 Global Genome Editing Technologies Market, Forecasted Estimates, till 2035 (USD Billion)
Figure 16.4 Global Genome Editing Technologies Market, Forecasted Estimates, till 2035: Conservative Scenario (USD Billion)
Figure 16.5 Global Genome Editing Technologies Market, Forecasted Estimates, till 2035: Optimistic Scenario (USD Billion)
Figure 17.1 Genome Editing Technologies Market: Distribution by Type of Payment Method Employed
Figure 17.2 Genome Editing Technologies Market for Milestone Payments: Forecasted Estimates, till 2035 (USD Million)
Figure 17.3 Genome Editing Technologies Market for Upfront Payments: Forecasted Estimates, till 2035 (USD Million)
Figure 18.1 Genome Editing Technologies Market: Distribution by Type of Gene Editing Technique
Figure 18.2 Genome Editing Technologies Market for CRISPR-Cas System: Forecasted Estimates, till 2035 (USD Million)
Figure 18.3 Genome Editing Technologies Market for TALENs: Forecasted Estimates, till 2035 (USD Million)
Figure 18.4 Genome Editing Technologies Market for Meganucleases: Forecasted Estimates, till 2035 (USD Million)
Figure 18.5 Genome Editing Technologies Market for ZFNs: Forecasted Estimates, till 2035 (USD Million)
Figure 18.6 Genome Editing Technologies Market for Other Techniques: Forecasted Estimates, till 2035 (USD Million)
Figure 19.1 Genome Editing Technologies Market: Distribution by Type of Gene Editing Approach
Figure 19.2 Genome Editing Technologies Market for Gene Knock-out: Forecasted Estimates, till 2035 (USD Million)
Figure 19.3 Genome Editing Technologies Market for Gene Knock-in: Forecasted Estimates, till 2035 (USD Million)
Figure 20.1 Genome Editing Technologies Market: Distribution by Type of Gene Delivery Method
Figure 20.2 Genome Editing Technologies Market for Ex vivo: Forecasted Estimates, till 2035 (USD Million)
Figure 20.3 Genome Editing Technologies Market for In vivo: Forecasted Estimates, till 2035 (USD Million)
Figure 21.1 Genome Editing Technologies Market: Distribution by Type of Gene Delivery Modality
Figure 21.2 Genome Editing Technologies Market for Viral Vectors: Forecasted Estimates, till 2035 (USD Million)
Figure 21.3 Genome Editing Technologies Market for Non-Viral Vectors: Forecasted Estimates, till 2035 (USD Million)
Figure 22.1 Genome Editing Technologies Market: Distribution by Type of Therapy
Figure 22.2 Genome Editing Technologies Market for Cell Therapies: Forecasted Estimates, till 2035 (USD Million)
Figure 22.3 Genome Editing Technologies Market for Gene Therapies: Forecasted Estimates, till 2035 (USD Million)
Figure 22.4 Genome Editing Technologies Market for Other Therapies: Forecasted Estimates, till 2035 (USD Million)
Figure 23.1 Genome Editing Technologies Market: Distribution by Application Area
Figure 23.2 Genome Editing Technologies Market for Drug Discovery and Development: Forecasted Estimates, till 2035 (USD Million)
Figure 23.3 Genome Editing Technologies Market for Diagnostics: Forecasted Estimates, till 2035 (USD Million)
Figure 24.1 Genome Editing Technologies Market: Distribution by Type of End User
Figure 24.2 Genome Editing Technologies Market for Pharmaceutical and Biotechnology Companies: Forecasted Estimates, till 2035 (USD Million)
Figure 24.3 Genome Editing Technologies Market for Academic and Research Institutes: Forecasted Estimates, till 2035 (USD Million)
Figure 25.1 Genome Editing Technologies Market: Distribution by Geographical Regions
Figure 25.2 Genome Editing Technologies Market in North America: Forecasted Estimates, till 2035 (USD Million)
Figure 25.3 Genome Editing Technologies Market in the US: Forecasted Estimates, till 2035 (USD Million)
Figure 25.4 Genome Editing Technologies Market in Canada: Forecasted Estimates, till 2035 (USD Million)
Figure 25.5 Genome Editing Technologies Market in Europe: Forecasted Estimates, till 2035 (USD Million)
Figure 25.6 Genome Editing Technologies Market in Germany: Forecasted Estimates, till 2035 (USD Million)
Figure 25.7 Genome Editing Technologies Market in France: Forecasted Estimates, till 2035 (USD Million)
Figure 25.8 Genome Editing Technologies Market in Ireland: Forecasted Estimates, till 2035 (USD Million)
Figure 25.9 Genome Editing Technologies Market in Asia-Pacific: Forecasted Estimates, till 2035 (USD Million)
Figure 25.10 Genome Editing Technologies Market in South Korea: Forecasted Estimates, till 2035 (USD Million)
Figure 25.11 Genome Editing Technologies Market in China: Forecasted Estimates, till 2035 (USD Million)
Figure 25.12 Genome Editing Technologies Market in Japan: Forecasted Estimates, till 2035 (USD Million)
Figure 25.13 Penetration Growth (P-G) Matrix: Key Geographical Regions
Figure 26.1 Genome Editing Technologies Market for Leading Industry Players (USD Million)
Figure 27.1 Concluding Remarks: Technology Landscape
Figure 27.2 Concluding Remarks: Partnerships and Collaborations
Figure 27.3 Concluding Remarks: Patent Analysis
Figure 27.4 Concluding Remarks: Funding and Investments Analysis
Figure 27.5 Concluding Remarks: Market Forecast and Opportunity Analysis
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Roots Analysis 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們